KRYS
Price
$326.55
Change
-$8.30 (-2.48%)
Updated
Oct 6, 04:43 PM (EDT)
Capitalization
9.98B
34 days until earnings call
Intraday BUY SELL Signals
OLMA
Price
$7.99
Change
-$0.26 (-3.15%)
Updated
Oct 6, 02:48 PM (EDT)
Capitalization
753.35M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KRYS vs OLMA

KRYS vs OLMA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KRYS vs. OLMA commentary
Oct 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and OLMA is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
KRYS vs OLMA: Fundamental Ratings
KRYS
OLMA
OUTLOOK RATING
1..100
5667
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
9100
SMR RATING
1..100
4698
PRICE GROWTH RATING
1..100
4688
P/E GROWTH RATING
1..100
26100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OLMA's Valuation (19) in the null industry is somewhat better than the same rating for KRYS (82) in the Pharmaceuticals Major industry. This means that OLMA’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for OLMA (100) in the null industry. This means that KRYS’s stock grew significantly faster than OLMA’s over the last 12 months.

KRYS's SMR Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for OLMA (98) in the null industry. This means that KRYS’s stock grew somewhat faster than OLMA’s over the last 12 months.

KRYS's Price Growth Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for OLMA (88) in the null industry. This means that KRYS’s stock grew somewhat faster than OLMA’s over the last 12 months.

KRYS's P/E Growth Rating (26) in the Pharmaceuticals Major industry is significantly better than the same rating for OLMA (100) in the null industry. This means that KRYS’s stock grew significantly faster than OLMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSOLMA
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 29 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
88%
COMPARISON
Comparison
Oct 06, 2026
Stock price -- (KRYS: $334.85 vs. OLMA: $8.25)
Brand notoriety: KRYS and OLMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 126% vs. OLMA: 84%
Market capitalization -- KRYS: $9.98B vs. OLMA: $753.35M
KRYS [@Biotechnology] is valued at $9.98B. OLMA’s [@Biotechnology] market capitalization is $753.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 2 FA rating(s) are green while OLMA’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 2 green, 3 red.
  • OLMA’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than OLMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while OLMA’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 5 bearish.
  • OLMA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, OLMA is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -0.66% price change this week, while OLMA (@Biotechnology) price change was -4.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.89%. For the same industry, the average monthly price growth was -14.49%, and the average quarterly price growth was -3.48%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 09, 2026.

OLMA is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-2.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KRYS
Daily Signal:
Gain/Loss:
OLMA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SVXY64.520.41
+0.64%
ProShares Short VIX Short-Term Futures ETF (SVXY)
VEU83.880.43
+0.52%
Vanguard FTSE All-World ex-US Index Fund (VEU)
HAIL34.330.12
+0.35%
State Street SPDR S&P Kensho Smart Mobility ETF (HAIL)
PDEC47.420.13
+0.29%
Innovator U.S. Equity Power Buffer ETF - December (PDEC)
INKM33.070.02
+0.06%
State Street Income Allocation ETF (INKM)